WASHINGTON (AP) — Healthpoint Ltd. and DFB Pharmaceuticals will pay up to $48 million to settle allegations that Healthpoint marketed a prescription skin ointment without approval from federal regulators.
The Justice Department said Healthpoint caused false claims for reimbursement to be submitted to Medicare and Medicaid for Xenaderm, which is used for treating nursing home patients' bed sores. Fort Worth, Texas-based Healthpoint is one of DFB's operating companies.
The government alleged that Healthpoint's business strategy was to market new prescription drugs modeled after products that were available before October 1962 in order to avoid the time, effort and expense of obtaining approval from the Food and Drug Administration. Products containing Xenaderm's principal active ingredient were on the market before 1962, but the FDA determined the ingredient was less-than-effective for its intended use.
Matt Vespa - Arby's Apologizes To Law Enforcement After Employee Refused To Serve Police Officer
Hugh Hewitt to Trump: Do you know who the Quds Force is? - Hot Air
Homemade Gunpowder from What? - Bearing Arms - Video
War on cops: Female officer in Penn. assaulted and thrown over guardrail after stopping to help disabled vehicle
How to Write a New York Times Op-Ed in Three Easy Steps | Human Events
Michael Schaus - Global Warming Tour Cut Off By--Wait for It-- Too Much Ice!
Obama's gun law enforcement at work: sell 55 illegal guns, get one year probation | RedState